Innovative Influenza Chemotherapeutics Targeting Viral Polymerase ID: 2017-070
An innovative approach to combat influenza by developing chemotherapeutics that target the virus's polymerase to prevent resistance.
Photo by Dr_Microbe - stock.adobe.com
Technology Overview
This technology focuses on the development of novel influenza chemotherapeutics, specifically nuclear import inhibitors that target a conserved site of the influenza polymerase subunit PB1. By honing in on viral proteins rather than host proteins, these inhibitors aim to provide a targeted, effective solution to combat influenza virus replication and resistance.
Key Advantages
- Targets viral proteins, reducing the risk of host toxicity
- Designed to minimize the development of drug resistance
- Offers a more specific approach to influenza treatment
- Potential for use in combination therapies, akin to HIV treatment strategies
Problems Addressed
- Resistance against existing influenza therapeutics due to virus mutability
- Limited effectiveness of previous antiviral drugs
- Emergence of novel, highly pathogenic influenza strains
Market Applications
- Pharmaceutical development for influenza treatment
- Combination therapy applications for managing influenza pandemics
- Research tools for studying influenza virus replication and resistance mechanisms
Additional Information
Technology ID: 2017-070
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report